AnPac Bio-Medical Science (NASDAQ: ANPC), a biotechnology company with operations in China and the United States focused on early cancer screening and detection, has reported its unaudited financial results and business highlights for the nine months ended Sept. 30, 2021. Financial highlights include total revenue reaching an estimated  $2.1 million, which is a 55.3% over the same period in 2020, and gross profit margin totaling 59.3%, representing an 8.8% increase from the year before. In addition, the average selling price of ANPC’s CDA-based tests was $71.6,  an increase of 72.3% from 2020. In addition, the company reported cash and cash equivalents of approximately $0.8 million for the nine-month period. Business highlights included AnPac’s acquisition of 60% equity interest in Anpai (Shanghai) Health Management Consulting Co. Ltd. as well as continued validation regarding the efficacy of its CDA testing obtained through clinical study follow-ups. The company also completed the development and evaluation of a second-generation cancer detection sensor, launched a joint venture designed to focus on a novel cancer-treatment technology and medical-device development, and filed 261 patent applications globally, among which 150 patents have been granted. AnPac is also continuing to build a proprietary cancer-risk assessment database, which totaled some 244,310 samples as of Sept. 30, 2021. “We are very pleased with our progress in research and development, commercialization, and operational performance for the first nine months in 2021,” said AnPac Bio chair and CEO Dr. Chris Yu in the press release. “We grew revenue by 55.3% and gross margin by 8.8 percentage points. At the same time, we reduced non-GAAP loss by 6.0%. Our number of issued patents, and clinical and commercial sample sizes all reached record high in Q3 2021. We are making solid progress in obtaining regulatory approval for our class III medical device for lung cancer assisting in diagnosis and have also submitted application for registration testing of our multi-cancer detection medical device for 11 types of cancer. We are also working very hard to obtain Laboratory Developed Test (‘LDT’) status for our CDA cancer test in the U.S. Based on our current status and progress, we now expect to obtain registration approval for our class III medical device (for lung cancer assisting in diagnosis) in late 2022.”

To view the full press release, visit https://ibn.fm/Y053A

About AnPac Bio-Medical Science Co. Ltd.

AnPac Bio is a biotechnology company focused on early cancer screening and detection, with 150 issued patents as of Sept. 30, 2021. With two certified clinical laboratories in China and one CLIA- and CAP-accredited clinical laboratory in the United States, AnPac Bio performs a suite of cancer screening and detection tests, including Cancer Differentiation Analysis (“CDA”), biochemical, immunological and genomics tests. According to Frost & Sullivan, AnPac Bio ranked third worldwide among companies offering next-generation, early cancer screening and detection technologies in terms of the number of clinical samples for cancer screening and detection in 2019. The company has a significant cancer screening and detection, based on approximately 43,980 clinical samples as of Sept. 30, 2021. AnPac Bio’s CDA technology platform has been shown in retrospective validation studies to detect the risk of more than 20 different cancer types with high sensitivity and specificity. For more information about the company, visit www.AnPacBio.com

NOTE TO INVESTORS: The latest news and updates relating to ANPC are available in the company’s newsroom at https://ibn.fm/ANPC

About BioMedWire

BioMedWire (BMW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) BioMedNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. BMW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, BMW brings its clients unparalleled visibility, recognition and brand awareness. BMW is where news, content and information converge.

To receive SMS text alerts from BioMedWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)

For more information please visit https://www.BioMedWire.com

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: http://BMW.fm/Disclaimer

BioMedWire (BMW)
San Francisco, California
www.BioMedWire.com
415.949.5050 Office
Editor@BioMedWire.com

BioMedWire is part of the InvestorBrandNetwork